Skip to main content
Premium Trial:

Request an Annual Quote

Heading to the Hill

Not only is FDA interested in learning more about direct-to-consumer genetic tests — the deputy director of the device evaluation section wrote a letter to the Pathway Genomics CEO asking him to provide the FDA clearance or approval number for Genetic Health Report or explain why he thinks it doesn't need clearance — so is the US House of Representatives. The Wall Street Journal reports that the House Energy and Commerce Committee wants more information about Pathway's test, as well as tests done by 23andMe and Navigenics. In particular, the panel is interested in how the test is analyzed, the accuracy of those analyses, and how the companies handle the samples and the information customers provide.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.